source
- FDA rejects Summit Therapeutics' ivonescimab combo, citing lack of survival benefit in lung cancerSummit Therapeutics and partner Akeso received a rejection from the U.S. Food and Drug Administration for their PD-1/VEGF antibody ivonescimab combined with chemotherapy. The agency said the data d…
- CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in studyCG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…